Authorised EU health claims for DHA and EPA
| Autor: | F.W. Vas Dias |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
chemistry.chemical_classification
Brain development Triglyceride business.industry Physiology Advertising Eicosapentaenoic acid chemistry.chemical_compound chemistry Health claims on food labels Docosahexaenoic acid Medicine Normal blood Normal vision business health care economics and organizations Polyunsaturated fatty acid |
| DOI: | 10.1016/b978-1-78242-382-9.00013-x |
| Popis: | The EU Register contains three authorised Article 13.1 health claims for the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) together, and for DHA alone, three Article 13.1 claims and three Article 14.1(b) claims. Considering EPA and DHA together, the claims relate to the maintenance of normal blood pressure, normal blood triglyceride levels and the normal function of the heart. The Article 13.1 claims for DHA concern the maintenance of normal brain function, normal vision and normal blood triglyceride levels. The DHA Article 14.1(b) claims all relate to children’s development and health, specifically to contributing towards normal brain development of the foetus and breastfed infant, normal development of the eye in the foetus and breastfed infant and contributing to normal visual development of infants up to 12 months of age. These authorised claims all come with conditions of use, which specify not only the amounts of the fatty acid(s) that should be contained in the food in order to carry the claim but also particular information statements that must appear on the food. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|